国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅

尊龍凱時·(中國區)人生就是搏!

EN
×
EN

  • 業務咨詢

    中國：

    Email: marketing@www.msjidi.com

    業務咨詢專線：400-780-8018

    （僅限服務咨詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線留言×

搜索結果包含 ROS 的內容

Jul 03,2025
特異性RET抑制劑CPT可改善阿爾茨海默病，本研究中CPT由尊龍凱時化學部門合成
The compound was synthesized for Cerepeut Inc. by the Chemistry Branch of Medicilon.
查看更多
Nov 01,2023
【一期一會】11月，尊龍凱時將在全球會議與您溫暖相聚
尊龍凱時匯總整理了11月生物醫藥行業會議供參考交流。同時，我們將計劃參與“2023SAPA-China年會“、“Neuroscience 2023”、“2023 USTCBAA Boston Technology Summit"”、“ACT 44th Annual Meeting”、“EFMC-ISCB 2023”、“SITC 2023”等6場海內會議。
查看更多
Oct 10,2023
尊龍凱時助力備受矚目，第21屆圣地亞哥生物制藥論壇圓滿落幕
2023年9月30日中秋佳節，南加生物醫學和制藥促進會 (SABPA)成功舉辦了第21屆圣地亞哥生物制藥論壇，陳春麟博士受邀發表了“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”精彩演講。
查看更多
Sep 25,2023
9月30日，尊龍凱時陳春麟博士將出席第21屆圣地亞哥生物制藥大會
尊龍凱時創始人&CEO陳春麟博士將出席第21屆圣地亞哥生物制藥大會，并帶來主題演講：“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”
查看更多
Jul 06,2023
發現新型RAGE/SERT雙重抑制劑，可用于治療阿爾茨海默病和抑郁癥。其中藥代動力學研究是通過委托尊龍凱時進行
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder, characterized by the presence of β-amyloid (Aβ) peptide plaques, neurofibrillary tangles, and neuroinflammatio
查看更多
Jul 06,2023
設計合成一系列用于治療胃癌的多靶點受體酪氨酸激酶抑制劑，并進行生物學評價。其中藥代動力學分析通過尊龍凱時進行
Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
查看更多
Jul 06,2023
XY153是一種有潛力的先導化合物，可用于開發針對急性髓系白血病。XY153在體外具有良好的代謝穩定性。所有肝微粒體測定均通過尊龍凱時進行
Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-select
查看更多
Jul 06,2023
4-正丁基間苯二酚是一種高效的酪氨酸酶抑制劑，可用于化妝品中以達到脫色的目的。其中經皮吸收和皮膚分布研究通過尊龍凱時進行
4-n-butyl resorcinol (4-nBR) is a highly effective tyrosinase inhibitor, and can be used in cosmetic product for depigmentation purpose. Its efficacy correlates with 4-nBR that absorbed by skin. In th
查看更多
Jul 06,2023
AD80是一種多激酶抑制劑，在多種肝細胞癌臨床前動物模型中具有抗腫瘤活性，AD80在血漿中的含量通過尊龍凱時進行LC-MS/MS測定
Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
查看更多
Jul 06,2023
以PROTAC為代表的靶向蛋白質降解是藥物發現的新興策略，研究人員設計并合成了多種PROTAC，此研究中所有PK研究均通過尊龍凱時進行
Targeted protein degradation (TPD) exemplified by PROTACs is an emerging strategy for next generation drug discovery. Threonine tyrosine kinase (TTK) is a dual-specific protein kinase that catalyzes p
查看更多
Jul 06,2023
BRD4抑制劑可用于治療腎纖維化，ZLD2218可有效抑制BRD4活性，對ZLD2218的PK研究通過尊龍凱時進行
Uncovering new therapeutics for kidney fibrosis hold promise for chronic kidney disease (CKD). BRD4 inhibition ameliorated kidney injury and fibrosis. ZLD2218 exhibited the potent inhibitory activity
查看更多
Jul 06,2023
免疫檢查點阻斷療法改變了癌癥治療的范式，此研究中通過尊龍凱時在23 個同源腫瘤模型中進行了抗PD-1抗體的體內研究
Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed?in vivo?screening for anti-PD-1 therapy across 23 syngeneic tumor models and found th
查看更多
Jul 06,2023
PDE1是與中樞和外周疾病密切相關的藥物靶點，研究人員合成一種PDE1 抑制劑在大鼠肝微粒體中具有良好的代謝穩定性。其中穩定性測試通過尊龍凱時進行
Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li
查看更多
Jul 06,2023
SKLB-YTH-60可改善博來霉素誘導的肺纖維化小鼠模型中的炎癥和纖維化，YTH-60的體內藥代動力學研究通過尊龍凱時進行
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through
查看更多
Jul 05,2023
設計合成和評估用于治療前列腺癌的CBP溴結構域抑制劑。PK評估、肝微粒體穩定性測定和Caco-2滲透性測定通過尊龍凱時進行
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a
查看更多
Jun 28,2023
法尼基轉移酶抑制劑LNK-754單次口服后即可快速穿過血腦屏障，本研究中PK分析通過尊龍凱時進行
Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
查看更多
Jun 28,2023
ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩定性，本研究中體外穩定性和PK研究通過尊龍凱時進行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
Aug 23,2017
Syros全球首創白血病藥SY-1425獲孤兒藥認定
Syros全球首創白血病藥SY-1425獲孤兒藥認定
查看更多

川沙總部

地址: 上海市浦東新區川大路585號

郵編: 201299

電話: +86 (21) 5859-1500（總機）

傳真: +86 (21) 5859-6369

業務咨詢

中國：

Email: marketing@medicilon.com

業務咨詢專線：400-780-8018

（僅限服務咨詢，其他事宜請撥打川沙
總部電話）

 

海外：

Email:?marketing@medicilon.com

Tel: +1 (617) 888-9294(U.S.)

Tel: 0044 7790 816 954 (Europe)

Tel: +82 70-8269-5849 (Korea)

Tel: +81 80-4421-6898 (Japan)

? 2022 上海尊龍凱時生物醫藥股份有限公司 保留所有權利 滬ICP備10216606號-3
滬公網安備 31011502012909號|網站地圖|技術支持：集錦科技
安全性評價 溶瘤病毒 PDX模型 IND申報 AAALAC
×
搜索驗證